{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:31:12Z","timestamp":1783636272226,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This study evaluates the potential superiority of combining paclitaxel-based hyperthermic intraperitoneal chemotherapy (HIPEC) with sequential intravenous neoadjuvant chemotherapy over intravenous neoadjuvant chemotherapy alone in Chinese patients with Federation of Gynecology and Obstetrics (FIGO) stage IIIC, IVA and IVB high-grade serous ovarian\/fallopian tube carcinoma (HGSOC). This interim analysis focuses on the safety and immediate efficacy of both regimens to determine the feasibility of the planned trial (C-HOC Trial).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a single-center, open-label, randomized control trial, FIGO stage IIIC, IVA, and IVB HGSOC patients (FAGOTTI score\u2009\u2265\u20098 during laparoscopic exploration) unsuitable for optimal cytoreduction in primary debulking surgery (PDS) were randomized 2:1 during laparoscopic exploration. The Experiment Group (HIPEC Group) received one cycle of intraperitoneal neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy (paclitaxel) followed by three cycles of intravenous chemotherapy (paclitaxel plus carboplatin), while the Control Group received only three cycles of intravenous chemotherapy. Both groups subsequently underwent interval debulking surgery (IDS). The adverse effects of chemotherapy, postoperative complications, and pathological chemotherapy response scores (CRS) after IDS were compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 65 enrolled patients, 39 HIPEC Group and 21 Control Group patients underwent IDS. Grade 3\u20134 chemotherapy-related adverse effects were primarily hematological with no significant differences between the two groups. The HIPEC Group exhibited a higher proportion of CRS 3 (20.5% vs. 4.8%; <jats:italic>P<\/jats:italic>\u2009=\u20090.000). R0 resection rates in IDS were 69.2% (HIPEC Group) and 66.7% (Control Group). R2 resection occurred in 2.6% (HIPEC Group) and 14.3% (Control Group) cases. No reoperations or postoperative deaths were reported, and complications were managed conservatively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Combining HIPEC with IV NACT in treating ovarian cancer demonstrated safety and feasibility, with no increased chemotherapy-related adverse effects or postoperative complications. HIPEC improved tumor response to neoadjuvant chemotherapy, potentially enhancing progression-free survival (PFS). However, the final overall survival results are pending, determining if HIPEC combined with IV NACT is superior to IV NACT alone.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-024-01468-3","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T11:02:41Z","timestamp":1720782161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The impact of Paclitaxel-based hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer patients - interim analysis of safety and immediate efficacy of a randomized control trial (C-HOC trial)"],"prefix":"10.1186","volume":"17","author":[{"given":"Qun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"issue":"1","key":"1468_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022 [J]. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"10177","key":"1468_CR2","first-page":"1240","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, et al. Epithel Ovarian cancer [J] Lancet. 2019;393(10177):1240\u201353.","journal-title":"Epithel Ovarian cancer [J] Lancet"},{"issue":"1","key":"1468_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41698-021-00247-3","volume":"6","author":"I Lodewijk","year":"2022","unstructured":"Lodewijk I, Bernardini A, Suarez-Cabrera C, et al. Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy [J]. NPJ Precis Oncol. 2022;6(1):7.","journal-title":"NPJ Precis Oncol"},{"issue":"13","key":"1468_CR4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","volume":"33","author":"D Tewari","year":"2015","unstructured":"Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study [J]. J Clin Oncol. 2015;33(13):1460\u20136.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1468_CR5","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1200\/JCO.2015.61.4776","volume":"33","author":"AA Wright","year":"2015","unstructured":"Wright AA, Cronin A, Milne DE, et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian Cancer [J]. J Clin Oncol. 2015;33(26):2841\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1468_CR6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Van Driel","year":"2018","unstructured":"Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer [J]. N Engl J Med. 2018;378(3):230\u201340.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"1468_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/1471-0528.17323","volume":"129","author":"MF Wu","year":"2022","unstructured":"Wu MF, Liang JX, Li H, et al. Effects of neoadjuvant hyperthermic intraperitoneal chemotherapy on chemotherapy response scores and recurrence in high-grade serous ovarian cancer patients with advanced disease: a multicentre retrospective cohort study [J]. BJOG. 2022;129(Suppl 2):5\u201313.","journal-title":"BJOG"},{"issue":"9","key":"1468_CR8","doi-asserted-by":"publisher","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","volume":"20","author":"DK Armstrong","year":"2022","unstructured":"Armstrong DK, Alvarez RD, Backes FJ, et al. NCCN Guidelines(R) insights: ovarian Cancer, Version 3.2022 [J]. J Natl Compr Canc Netw. 2022;20(9):972\u201380.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1468_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ygyno.2010.09.010","volume":"120","author":"GD Aletti","year":"2011","unstructured":"Aletti GD, Eisenhauer EL, Santillan A, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment [J]. Gynecol Oncol. 2011;120(1):23\u20138.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1468_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ijrobp.2007.06.022","volume":"70","author":"M Palazzi","year":"2008","unstructured":"Palazzi M, Tomatis S, Orlandi E, et al. Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system [J]. Int J Radiat Oncol Biol Phys. 2008;70(2):330\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"1468_CR11","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","volume":"33","author":"S Bohm","year":"2015","unstructured":"Bohm S, Faruqi A, Said I, et al. Chemotherapy response scores: development and validation of a system to quantify histopathologic response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma [J]. J Clin Oncol. 2015;33(22):2457\u201363.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1468_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","volume":"157","author":"MC Lim","year":"2022","unstructured":"Lim MC, Chang SJ, Park B, et al. Survival after Hyperthermic Intraperitoneal Chemotherapy and primary or interval cytoreductive surgery in ovarian Cancer: a randomized clinical trial [J]. JAMA Surg. 2022;157(5):374\u201383.","journal-title":"JAMA Surg"},{"issue":"Suppl 1","key":"1468_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ijgo.13882","volume":"155","author":"S Kehoe","year":"2021","unstructured":"Kehoe S, Bhatla N. FIGO Cancer Report 2021 [J]. Int J Gynaecol Obstet. 2021;155(Suppl 1):5\u20136.","journal-title":"Int J Gynaecol Obstet"},{"key":"1468_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","volume":"59","author":"A Fagotti","year":"2016","unstructured":"Fagotti A, Ferrandina G, Vizzielli G, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome [J]. Eur J Cancer. 2016;59:22\u201333.","journal-title":"Eur J Cancer"},{"issue":"9990","key":"1468_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial [J]. Lancet. 2015;386(9990):249\u201357.","journal-title":"Lancet"},{"issue":"2","key":"1468_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/bjc.2014.602","volume":"112","author":"L Ansaloni","year":"2015","unstructured":"Ansaloni L, Coccolini F, Morosi L, et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer [J]. Br J Cancer. 2015;112(2):306\u201312.","journal-title":"Br J Cancer"},{"issue":"5","key":"1468_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1080\/02656736.2017.1291999","volume":"33","author":"L Lemoine","year":"2017","unstructured":"Lemoine L, Sugarbaker P, Van Der Speeten K. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma [J]. Int J Hyperth. 2017;33(5):582\u201392.","journal-title":"Int J Hyperth"},{"issue":"3","key":"1468_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000324395","volume":"46","author":"M Muller","year":"2011","unstructured":"Muller M, Cherel M, Dupre PF, et al. Cytotoxic effect of hyperthermia and chemotherapy with platinum salt on ovarian cancer cells: results of an in vitro study [J]. Eur Surg Res. 2011;46(3):139\u201347.","journal-title":"Eur Surg Res"},{"key":"1468_CR19","doi-asserted-by":"crossref","unstructured":"Kong XX, Jiang S, Liu T et al. Paclitaxel increases sensitivity of SKOV3 cells to hyperthermia by inhibiting heat shock protein 27 [J]. Biomed Pharmacother, 2020, 132(110907.","DOI":"10.1016\/j.biopha.2020.110907"},{"key":"1468_CR20","doi-asserted-by":"crossref","unstructured":"Colombo N, Sessa C, Du Bois A et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger [J]. Ann Oncol, 2019, 30(5): 672\u2013705.","DOI":"10.1093\/annonc\/mdz062"},{"issue":"8","key":"1468_CR21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/modpathol.2015.77","volume":"28","author":"WG Mccluggage","year":"2015","unstructured":"Mccluggage WG, Judge MJ, Clarke BA, et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International collaboration on Cancer Reporting (ICCR) [J]. Mod Pathol. 2015;28(8):1101\u201322.","journal-title":"Mod Pathol"},{"issue":"2","key":"1468_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","volume":"154","author":"PA Cohen","year":"2019","unstructured":"Cohen PA, Powell A, Bohm S, et al. Pathological chemotherapy response scores is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data [J]. Gynecol Oncol. 2019;154(2):441\u20138.","journal-title":"Gynecol Oncol"},{"issue":"7766","key":"1468_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-019-1382-1","volume":"571","author":"P Jonsson","year":"2019","unstructured":"Jonsson P, Bandlamudi C, Cheng ML, et al. Tumour lineage shapes BRCA-mediated phenotypes [J]. Nature. 2019;571(7766):576\u20139.","journal-title":"Nature"},{"issue":"3","key":"1468_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P Disilvestro","year":"2023","unstructured":"Disilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance olaparib at a 7-Year Follow-Up in patients with newly diagnosed Advanced Ovarian Cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial [J]. J Clin Oncol. 2023;41(3):609\u201317.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1468_CR25","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed Advanced Ovarian Cancer [J]. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"4","key":"1468_CR26","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.3802\/jgo.2019.30.e59","volume":"30","author":"M Petrillo","year":"2019","unstructured":"Petrillo M, Zucchetti M, Cianci S, et al. Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study [J]. J Gynecol Oncol. 2019;30(4):e59.","journal-title":"J Gynecol Oncol"},{"issue":"6","key":"1468_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ctrv.2006.07.006","volume":"32","author":"E De Bree","year":"2006","unstructured":"De Bree E, Theodoropoulos PA, Rosing H, et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside [J]. Cancer Treat Rev. 2006;32(6):471\u201382.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"1468_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5","volume":"83","author":"MV Blagosklonny","year":"1999","unstructured":"Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review) [J]. Int J Cancer. 1999;83(2):151\u20136.","journal-title":"Int J Cancer"},{"issue":"18","key":"1468_CR29","first-page":"4625","volume":"59","author":"PA Theodoropoulos","year":"1999","unstructured":"Theodoropoulos PA, Polioudaki H, Kostaki O, et al. Taxol affects nuclear lamina and pore complex organization and inhibits import of karyophilic proteins into the cell nucleus [J]. Cancer Res. 1999;59(18):4625\u201333.","journal-title":"Cancer Res"},{"issue":"18","key":"1468_CR30","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/jnci\/88.18.1308","volume":"88","author":"CG Milross","year":"1996","unstructured":"Milross CG, Mason KA, Hunter NR, et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel [J]. J Natl Cancer Inst. 1996;88(18):1308\u201314.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"1468_CR31","first-page":"4610","volume":"6","author":"WF Symmans","year":"2000","unstructured":"Symmans WF, Volm MD, Shapiro RL, et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment [J]. Clin Cancer Res. 2000;6(12):4610\u20137.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1468_CR32","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1245\/s10434-007-9792-y","volume":"15","author":"E De Bree","year":"2008","unstructured":"De Bree E, Rosing H, Filis D, et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study [J]. Ann Surg Oncol. 2008;15(4):1183\u201392.","journal-title":"Ann Surg Oncol"},{"key":"1468_CR33","doi-asserted-by":"crossref","unstructured":"Wu MF, Cheng XY, Wang DY et al. Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: a multicenter phase I trial [J]. Gynecol Oncol, 2023, 181(125\u2009\u2013\u200932.","DOI":"10.1016\/j.ygyno.2023.12.019"},{"issue":"2","key":"1468_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1634\/theoncologist.10-2-112","volume":"10","author":"PH Sugarbaker","year":"2005","unstructured":"Sugarbaker PH, Mora JT, Carmignani P, et al. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy [J]. Oncologist. 2005;10(2):112\u201322.","journal-title":"Oncologist"},{"issue":"2","key":"1468_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jso.21448","volume":"101","author":"JH Kim","year":"2010","unstructured":"Kim JH, Lee JM, Ryu KS, et al. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer [J]. J Surg Oncol. 2010;101(2):149\u201355.","journal-title":"J Surg Oncol"},{"issue":"1","key":"1468_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ygyno.2007.03.019","volume":"106","author":"JH Bae","year":"2007","unstructured":"Bae JH, Lee JM, Ryu KS, et al. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery [J]. Gynecol Oncol. 2007;106(1):193\u2013200.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1468_CR37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.suronc.2016.05.010","volume":"25","author":"P Cascales-Campos","year":"2016","unstructured":"Cascales-Campos P, Lopez-Lopez V, Gil J, et al. Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C\/IV ovarian cancer. Is there any difference? [J]. Surg Oncol. 2016;25(3):164\u201370.","journal-title":"Surg Oncol"},{"issue":"1","key":"1468_CR38","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.3802\/jgo.2019.30.e3","volume":"30","author":"YJ Lee","year":"2019","unstructured":"Lee YJ, Lee JY, Cho MS, et al. Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study [J]. J Gynecol Oncol. 2019;30(1):e3.","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"1468_CR39","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/curroncol31020048","volume":"31","author":"P Villarejo Campos","year":"2024","unstructured":"Villarejo Campos P, Sanchez Garcia S, Amo-Salas M, et al. Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for ovarian peritoneal metastases: a Randomized Phase III Clinical Trial (HIPECOVA) [J]. Curr Oncol. 2024;31(2):660\u201371.","journal-title":"Curr Oncol"},{"issue":"3","key":"1468_CR40","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.ygyno.2020.09.022","volume":"159","author":"LM Charo","year":"2020","unstructured":"Charo LM, Jou J, Binder P, et al. Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States [J]. Gynecol Oncol. 2020;159(3):681\u20136.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1468_CR41","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ygyno.2020.06.487","volume":"158","author":"LM Chambers","year":"2020","unstructured":"Chambers LM, Costales AB, Crean-Tate K, et al. A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology [J]. Gynecol Oncol. 2020;158(3):794\u2013802.","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-024-01468-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-024-01468-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-024-01468-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T11:04:41Z","timestamp":1720782281000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-024-01468-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1468"],"URL":"https:\/\/doi.org\/10.1186\/s13048-024-01468-3","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"24 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study received approval from the Internal Review Board of the Ruijin Hospital(Board of Ethics Committee of Ruijin Hospital). This study was registered on Jan 6<sup>th,<\/sup> 2020 at the Chinese Clinical Trial Registry platform, Registration number: ChiCTR2000028894. The study adhered to the principles outlined in the Declaration of Helsinki (revised in 2013).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was diligently obtained from all enrolled patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publication"}}],"article-number":"145"}}